Drugmaker Biocon is banking on the ramp-up of interchangeable biosimilar insulin glargine expecting the product to boost the revenue and pr...

The listing is expected to boost Biocon's biosimilar business, as inclusion of Semglee on Express Scripts' NPF will allow pharmacies to sub...

To encourage broad patient access to this important medicine, Mylan is offering Semglee at a wholesale acquisition cost (WAC)[1] of $147.98...

“This is to inform you that Biocon Sdn Bhd, a subsidiary of Biocon, has received the EIR from the USFDA for the pre-approval inspection of ...

US District Court of New Jersey found the device patent claims (US Patent No. 9526844) asserted by Sanofi against Biocon and Mylan’s insuli...

USFDA had conducted a pre-approval inspection of Biocon's subsidiary Biocon Sdn BHd's manufacturing facility in Malaysia for Insulin Glargi...

The biotechnology major and pharmaceutical company Mylan N V announced the launch of their insulin biosimilar Semglee.

Biocon is confident of addressing these observations through a corrective and preventive action plan in a timely manner, it added.

The integrated insulins facility in Malaysia manufactures drug substance and drug products in vials, cartridges, and insulin delivery devic...

Firms have been asked to share details about a change in the manufacturing site for glargine from Bengaluru to a new facility in Malaysia.

Mylan and Biocon, which have co-developed insulin glargine, look forward to offering another insulin treatment option for diabetic patients.

In March this year, Biocon received approval from the Japanese health authority to sell its biosimilar product Insulin Glargine.

Biocon has received approval from the Japanese health authority to sell its biosimilar product 'Insulin Glargine' in that country.

Biocon rallied a little over 3% in trade on Friday, after the biotechnology major said that it has received approval for its insulin Glargi...

Galactus by PiSA is the first insulin Glargine to be approved in Mexico as per the biocomparable approvals pathway defined in 2012, it adde...

As per the strategic distribution pact inked between the two companies, Mumbai-based Lupin will launch LG Life Sciences' Insulin Glargine.

Wockhardt and Biocon have come under the drug price regulator National Pharmaceutical Pricing Authority (NPPA) scanner for allegedly violat...